齐拉西酮与利培酮治疗精神分裂症患者的对照研究

Comparison of efficacy and safety of ziprasidone and risperidone in treating patients with schizophrenia

目的:比较齐拉西酮与利培酮治疗精神分裂症患者的疗效与不良反应。方法:120例符合中国精神障碍分类与诊断标准第3版精神分裂症诊断标准的患者随机分为两组,每组60例,分别给予齐拉西酮与利培酮治疗8周,采用阳性与阴性症状量表(PANSS)评定疗效,治疗中出现的症状量表(TESS)评定不良反应,用世界卫生组织编制的生活质量量表(WHOQOL-100)评定生活质量。结果:治疗8周后,齐拉西酮组显效率73.3%,有效率90.0%,利培酮组显效率66.7%,总有效率86.7%,两组疗效比较差异无统计学意义(P>0.05);两组WHOQOL-100各领域评分较治疗前均明显改善(P>0.01);齐拉西酮组不良反应发生率16.7%,利培酮组为13.3%,两组差异无统计学意义(P>0.05)。结论:齐拉西酮与利培酮治疗精神分裂症患者的疗效相当,不良反应小,明显改善患者生活质量。

Objective： To compare the efficacy and safety between ziprasidone and risperidone in treatment of schizophrenia. Method ： one hundered and twenty patients with schizophrenia who met the schizophrenia criterion of Chinese classification of mental disorders were devided into two groups ramdomly and treated with ziprasidone or risperidone for 8 weeks respectively. The positive and negative scale （PANSS） and treatment emergent side effect scale （TESS） were used to evaluate the efficacy and adverse effect respectively, the quality of life was measured by World Health Organization quality of life questionnaire （WHOQOL-100）. Results ： The significant efficacy rate of ziprasidone group was 73.3% and the efficacy rate was 90.0% after 8 weeks, while 66.7% and 86.7% in risperidone group. There were no statistical difference between two groups（ P 〉 0.05）. The two groups showed similar improvement on quality of life. The incidence rate of adverse effect was 16.7% in ziprasidone group and that was 13.3% in risperidone group,without statistical differece between them （P 〉 0.05 ）. Conclusion： Ziprasidone and risperidonis are similarly effective and safe in the treatment of schizophrenia with improving the patients, quality of life and mild side effects.